Literature DB >> 2350531

Metabolism of ciamexon by human liver microsomes: an investigation into the formation of stable, chemically reactive and cytotoxic metabolites.

M D Tingle1, B K Park.   

Abstract

1. The in vitro generation of stable, protein-reactive and cytotoxic metabolites from ciamexon by human liver microsomes has been assessed. Stable metabolites were characterized by h.p.l.c./mass spectrometry, protein reactive metabolites by radiometric analysis and cytotoxic metabolites by assessment of cell viability after exposure to metabolites formed in situ. 2. Human livers were obtained from renal transplant donors. All 16 livers investigated metabolized ciamexon in a NADPH-dependent reaction, the major metabolite being the 6-hydroxy-methyl derivative. The hydroxylase activity of the livers varied from 34-577 pmol mg-1 min-1, with a mean activity of 306 +/- 156 pmol mg-1 min-1. The further oxidation product, 6-carboxy ciamexon, was also detected in some incubations. A third, unidentified, polar metabolite was present in all incubations (3.34-11.11% of incubated radioactivity). 3. Only very low levels (less than 1%) of radioactivity became irreversibly bound to microsomal protein, which suggests that ciamexon undergoes little or no oxidative bioactivation in vitro. 4. Human liver microsomes did not metabolize ciamexon to a cytotoxic species, whereas microsomes prepared from mouse livers did generate a cytotoxic species. The degree of toxicity was enhanced if animals were pre-treated with either phenobarbitone or beta-naphthoflavone.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2350531      PMCID: PMC1380154          DOI: 10.1111/j.1365-2125.1990.tb03678.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

Review 1.  Halothane hepatitis: a model of immune mediated drug hepatotoxicity.

Authors:  J Neuberger; J G Kenna
Journal:  Clin Sci (Lond)       Date:  1987-03       Impact factor: 6.124

2.  Separation of lymphocytes, granulocytes, and monocytes from human blood using iodinated density gradient media.

Authors:  A Bøyum
Journal:  Methods Enzymol       Date:  1984       Impact factor: 1.600

3.  Suppression of spontaneous insulin-dependent diabetes in BB rats by administration of ciamexone.

Authors:  U Kiesel; K Maruta; U Treichel; U Bicker; H Kolb
Journal:  J Immunopharmacol       Date:  1986

4.  The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites.

Authors:  H S Purba; J L Maggs; M L Orme; D J Back; B K Park
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

Review 5.  Activation mechanisms to chemical toxicity.

Authors:  D V Parke
Journal:  Arch Toxicol       Date:  1987       Impact factor: 5.153

6.  The binding of ciamexone to globin: its demonstration and some accompanying effects in rats.

Authors:  B Isert; G Götz; K T van der Trenck; K D Friedberg
Journal:  Toxicol Appl Pharmacol       Date:  1987-03-15       Impact factor: 4.219

7.  Measurement and characterization of membrane-bound and soluble epoxide hydrolase activities in resting mononuclear leukocytes from human blood.

Authors:  J Seidegård; J W DePierre; R W Pero
Journal:  Cancer Res       Date:  1984-09       Impact factor: 12.701

8.  The influence on the formation of unstable haemoglobin by the immunomodulating 2-cyanaziridines azimexone and BM 41.332 in mice.

Authors:  B Isert; K Mengel; U Bicker; K D Friedberg
Journal:  J Immunopharmacol       Date:  1985

9.  In vitro evaluation of a toxic metabolite of sulfadiazine.

Authors:  N H Shear; S P Spielberg
Journal:  Can J Physiol Pharmacol       Date:  1985-11       Impact factor: 2.273

10.  Metabolic basis of adverse drug reactions.

Authors:  B K Park
Journal:  J R Coll Physicians Lond       Date:  1986-07
View more
  1 in total

1.  The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes.

Authors:  V Spaldin; S Madden; W F Pool; T F Woolf; B K Park
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.